Form 4: United Therapeutics CEO Martine Rothblatt Executes Stock Option Exercise and Sale Plan
SEC Form 4 Filing
Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales of common stock under a pre-arranged 10b5-1 trading plan on August 20 and 21, 2024.
Summary
- Martine Rothblatt, the Chairperson and CEO of United Therapeutics, engaged in transactions involving the exercise of stock options and the sale of common stock on August 20 and 21, 2024.
- These transactions were executed under a pre-arranged 10b5-1 trading plan established on August 4, 2023.
- On both days, 3,600 stock options were exercised at a price of $129.49 per share.
- Subsequent sales of common stock occurred at varying prices, ranging from approximately $341.28 to $353.17 on August 20 and $346.07 to $352.98 on August 21.
- The sales resulted in a decrease in the number of shares directly owned by Rothblatt, while the number of shares held indirectly through various trusts remained substantial.
- The trading plan is set to continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
Sentiment
Score: 6
Explanation: The document is a routine disclosure of stock transactions by a company executive under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment, but rather reflects standard corporate governance and executive compensation practices.
Future Outlook
The 10b5-1 trading plan will continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
Industry Context
Executive stock option exercises and sales are common practice, often governed by pre-arranged trading plans to avoid insider trading concerns. The 10b5-1 plan allows insiders to sell shares at predetermined times and prices, providing transparency and compliance with securities regulations.
Comparison to Industry Standards
- Executive compensation practices, including stock options, are common across publicly traded companies.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation packages.
- The use of 10b5-1 trading plans is a standard practice among executives to manage their stock holdings and avoid accusations of insider trading.
- The size and frequency of stock option exercises and sales can vary widely depending on the company's performance, executive compensation structure, and individual financial planning.
Key Dates
| Date | Description |
|---|---|
| 12/31/2014 | Date stock options were exercisable |
| 08/04/2023 | Date of establishment of the 10b5-1 trading plan |
| 08/20/2024 | Date of first transaction (stock option exercise and sale) |
| 08/21/2024 | Date of second transaction (stock option exercise and sale) |
| 08/22/2024 | Date of filing |
| 08/31/2024 | Potential end date of the 10b5-1 trading plan |
| 12/31/2024 | Expiration date of the tranche of 723,869 stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.